Alprazolam

Generic Name
Alprazolam
Brand Names
Niravam, Xanax
Drug Type
Small Molecule
Chemical Formula
C17H13ClN4
CAS Number
28981-97-7
Unique Ingredient Identifier
YU55MQ3IZY
Background

Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effe...

Indication

Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.

Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.

Associated Conditions
Generalized Anxiety Disorder, Panic Disorder
Associated Therapies
-
Clinical Trials
Related News

A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions

Phase 1
Withdrawn
Conditions
Healthy
Interventions
Drug: Alprazolam
First Posted Date
2010-01-11
Last Posted Date
2021-01-28
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Registration Number
NCT01046162

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

First Posted Date
2009-09-11
Last Posted Date
2013-04-02
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT00975481

Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Alprazolam
First Posted Date
2009-04-09
Last Posted Date
2009-11-25
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
18
Registration Number
NCT00878865
Locations
🇫🇮

Orion Pharma phase I unit, Espoo, Finland

Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Xanax
Drug: Alprazolam
First Posted Date
2009-04-09
Last Posted Date
2009-11-25
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
18
Registration Number
NCT00878514
Locations
🇫🇮

Orion Pharma Phase I unit, Espoo, Finland

Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population

First Posted Date
2008-12-18
Last Posted Date
2021-01-28
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
24
Registration Number
NCT00810316
Locations
🇲🇽

Pfizer Investigational Site, Col. Arenal Tepepan, Mexico D.F., Mexico

Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment

First Posted Date
2008-12-05
Last Posted Date
2021-08-19
Lead Sponsor
University of Buenos Aires
Target Recruit Count
150
Registration Number
NCT00803400
Locations
🇦🇷

Psychiatry Academic Unit at J.A.Fernandez Hospital, University of Buenos Aires Medicine School Department of Mental Health, Buenos Aires, Capital Federal, Argentina

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

Not Applicable
Completed
Conditions
Type 1 Diabetes
Interventions
Other: control group
Drug: Alprazolam
First Posted Date
2008-01-14
Last Posted Date
2014-12-11
Lead Sponsor
Vanderbilt University
Target Recruit Count
56
Registration Number
NCT00592332
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

Phase 1
Terminated
Conditions
Healthy
Interventions
Other: Placebo
Drug: PF-00572778
Drug: alprazolam
First Posted Date
2007-12-24
Last Posted Date
2009-09-14
Lead Sponsor
Pfizer
Target Recruit Count
47
Registration Number
NCT00580190
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

Early Phase 1
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: Placebo
Drug: Alprazolam
First Posted Date
2007-12-17
Last Posted Date
2019-09-12
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
14
Registration Number
NCT00574639
Locations
🇺🇸

University of Maryland, Baltimore, Baltimore, Maryland, United States

A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder

First Posted Date
2007-11-07
Last Posted Date
2017-08-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
35
Registration Number
NCT00555139
Locations
🇪🇸

GSK Investigational Site, Terrassa - Barcelona, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy